High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure

Leukemia

Volumn 11, Issue 10, 1997, Pages 1654-1660

  Pedersen Bjergaard, J ^a   Pedersen, M ^a   Myhre, J ^a   Geisler, C ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Autologous stem cell transplantation; BEAM chemotherapy; Malignant lymphomas; Secondary leukemia; Therapy related leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RISK; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0030665754     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400809     Document Type: Article

References (27)

1. Witherspoon RP, Fischer LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Doney K, Thomas D, Storb R, Thomas ED. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
2. Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, Atkins H, Sutcliffe S, Messner H. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-2192.
3. Bhatia S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
4. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Myelodysplasia occurring after autologous bone marrow transplantation (ABMT) for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Blood 1993; 82: 455a.
5. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation : an additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
6. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Kessinger A, Armitage JO. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies, J Clin Oncol 1994; 12: 2527-2534.
7. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542.
8. Andre M, Henry-Amar M, Balise D, Colombat P, Fleury J, Milpied N, Chan JY, Pico JL, Bastion Y, Kuentz M, Biron P, Fermé C, Gisselbrecht C. Incidence of second cancers (SC) and causes of death after autologous stem cell transplantation (ASCT) for Hodgkin's disease (HD). Blood 1995; 86: 460a.
9. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994; 83: 3437-3440.
10. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
11. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
12. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. New Engl J Med 1989; 321: 1080-1085.
13. Barr BBB, Benton EC, McLaren K, Bunney MH, Smith IW, Blessing K, Hunter JAA. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989; I: 124-129.
14. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen N. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 1985; 103: 195-200.
15. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen SO, Rorth M, Mouridsen H, Dombernowsky P. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-1451.
16. Pedersen-Bjergaard J, Daugard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet 1991; 338: 359-363.
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias: French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
18. Mitelman F (ed). ISCN 1995, an International System for Human Cytogenetic Nomenclature. Karger: Farmington, CT, 1995.
19. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br j Cancer 1977; 35: 1-39.
22. Pedersen-Bjergaard J, Larsen SO, Struck J, Hansen HH, Specht L, Ersboll J, Hansen MM, Nissen NI. Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Lancet 1987; 1: 83-88.
23. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Colomb HM, Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7. J Clin Oncol 1986;4: 325-345.
24. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 1991; 47: 17-27.
25. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147-1148.
26. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood 1992; 79: 1892-1893.
27. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, Slovak ML, Nagasawa LS, Blume KG, Forman SJ. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease, J Clin Oncol 1991; 9: 1575-1579.